History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
Austen B Casey, Boris D. Heifets
British Journal of Pharmacology October 21, 2025 DOI: 10.1111/bph.70225 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Mechanism biology Drugs of abuse Clinical practice Therapeutic approach Medline Psychotherapist |
| Citations | 3 |
| Key findings | MDMA's therapeutic effects in PTSD psychotherapy likely involve prosocial behavior, reduced threat perception, and euphoria mediated by serotonin, but the mechanisms remain poorly defined and require further study. |
Abstract
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic stress disorder (PTSD), although the underlying mechanisms are poorly defined. In this review, we contextualize the emergence of MDMA-assisted psychotherapy (MDMA-AT) within 20th century psychiatry and trace its journey from assisting with military interrogation, through prohibition and to clinical use. We outline three core domains of MDMA's subjective effects-prosocial behaviour, reduced threat perception and euphoria-and explore how each may relate to its therapeutic efficacy and abuse liability. Drawing from clinical, behavioural, and pharmacological studies, we highlight the central role of 5-HT (serotonin) in mediating the effects of MDMA, while identifying key gaps in our understanding of its mechanism of action. We also assess how preclinical models capture therapeutic-relevant processes, discuss the limitations of existing data (including sex biases and an assumed role for therapeutic alliance) and suggest strategies to unravel the neurobiological basis of MDMA's therapeutic effects. Clarifying these mechanisms will be critical for optimizing future clinical protocols, mitigating risks and guiding the clinical development of safer, mechanistically informed MDMA-like therapeutic agents.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cited by 4
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review Life August 14, 2026
- R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. ACS Chemical Neuroscience May 6, 2026
- New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report Case Reports in Psychiatry 2026
- Emerging therapeutic opportunities for psychedelic and related drugs. British Journal of Pharmacology July 1, 2026
Cites 80
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences March 1, 1992
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacology March 3, 2006
and 75 more in the library